This company listing is no longer active
2NJ Stock Overview
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2NJ from our risk checks.
Covetrus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.52 |
| 52 Week High | US$21.60 |
| 52 Week Low | US$12.89 |
| Beta | 1.51 |
| 1 Month Change | 3.96% |
| 3 Month Change | 6.06% |
| 1 Year Change | 25.85% |
| 3 Year Change | 119.59% |
| 5 Year Change | n/a |
| Change since IPO | -34.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2NJ | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -1.8% | 1.8% |
| 1Y | 25.8% | -3.5% | 4.2% |
Return vs Industry: 2NJ exceeded the German Healthcare industry which returned -47.3% over the past year.
Return vs Market: 2NJ exceeded the German Market which returned -28.4% over the past year.
Price Volatility
| 2NJ volatility | |
|---|---|
| 2NJ Average Weekly Movement | 2.4% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2NJ has not had significant price volatility in the past 3 months.
Volatility Over Time: 2NJ's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 4,873 | Ben Wolin | www.covetrus.com |
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners.
Covetrus, Inc. Fundamentals Summary
| 2NJ fundamental statistics | |
|---|---|
| Market cap | €3.01b |
| Earnings (TTM) | -€13.31m |
| Revenue (TTM) | €4.76b |
0.6x
P/S Ratio-226.3x
P/E RatioIs 2NJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2NJ income statement (TTM) | |
|---|---|
| Revenue | US$4.65b |
| Cost of Revenue | US$3.77b |
| Gross Profit | US$882.00m |
| Other Expenses | US$895.00m |
| Earnings | -US$13.00m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.093 |
| Gross Margin | 18.97% |
| Net Profit Margin | -0.28% |
| Debt/Equity Ratio | 68.7% |
How did 2NJ perform over the long term?
See historical performance and comparison